Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors

NCT01011972 is registered in ClinicalTrials.gov with Mersana Therapeutics as lead sponsor.

NCT NCT01011972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01011972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Safety and Pharmacokinetics of XMT-1107 Administered as an Intravenous Infusion Once Every Three Weeks to Patients With Advanced Solid Tumors
Lead sponsor
Mersana Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2010
Completion date
September 30, 2013
Enrollment
52 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis